Seminars in Oncology
Volume 30, Issue 2 , Pages 142-145 , April 2003

Genetics and cytogenetics of Waldenstrom's macroglobulinemia

References 

  1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al.  Waldenstrom's macroglobulinemia: Clinical features, complications, and management. J Clin Oncol. 2000;18:214–226
  2. Gertz MA, Fonseca R, Rajkumar SV. Waldenstrom's macroglobulinemia. Oncologist. 2000;5:63–67
  3. Harris NL, Jaffe ES, Stein H, et al.  A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood. 1994;84:1361–1392
  4. Offit K, Parsa NZ, Filippa D, et al.  t(9;14)(p13;q32) denotes a subset of low-grade non-Hodgkin's lymphoma with plasmacytoid differentiation. Blood. 1992;80:2594–2599
  5. Morrison AM, Jager U, Chott A, et al.  Deregulated PAX-5 transcription from a translocated IgH promoter in marginal zone lymphoma. Blood. 1998;92:3865–3878
  6. Singh M, Birshtein BK. NF-HB (BSAP) is a repressor of the murine immunoglobulin heavy-chain 3′ alpha enhancer at early stages of B-cell differentiation. Mol Cell Biol. 1993;13:3611–3622
  7. Neurath MF, Strober W, Wakatsuki Y. The murine Ig 3′ alpha enhancer is a target site with repressor function for the B cell lineage-specific transcription factor BSAP (NF-HB, S alpha-BP). J Immunol. 1994;153:730–742
  8. Neurath MF, Max EE, Strober W. Pax5 (BSAP) regulates the murine immunoglobulin 3′ alpha enhancer by suppressing binding of NF-alpha P, a protein that controls heavy chain transcription. Proc Natl Acad Sci USA. 1995;92:5336–5340
  9. Max EE, Wakatsuki Y, Neurath MF, et al.  The role of BSAP in immunoglobulin isotype switching and B-cell proliferation. Curr Topics Microbiol Immunol. 1995;194:449–458
  10. Neurath MF, Stuber ER, Strober W. BSAP: A key regulator of B-cell development and differentiation. Immunol Today. 1995;16:564–569
  11. Chong YY, Lau LC, Lui WO, et al.  A case of t(8;14) with total and partial trisomy 3 in Waldenstrom macroglobulinemia. Cancer Genet Cytogenet. 1998;103:65–67
  12. San Roman C, Ferro T, Guzman M, et al.  Clonal abnormalities in patients with Waldenstrom's macroglobulinemia with special reference to a Burkitt-type t(8;14). Cancer Genet Cytogenet. 1985;18:155–158
  13. Nishida K, Taniwaki M, Misawa S, et al.  Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res. 1989;49:1275–1281
  14. Calasanz MJ, Cigudosa JC, Odero MD, et al.  Cytogenetic analysis of 280 patients with multiple myeloma and related disorders: primary breakpoints and clinical correlations. Genes Chromosomes Cancer. 1997;18:84–93
  15. Schop R, Kuehl W, Van Wier S, et al.  Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions. Blood. 2002;100:2996–3001
  16. Mansoor A, Medeiros LJ, Weber DM, et al.  Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Chromosomal abnormalities are associated with the polymorphous subtype and an aggressive clinical course. Am J Clin Pathol. 2001;116:543–549
  17. Louviaux I, Michaux L, Hagemeijer A, et al.  Cytogenetic abnormalities in Waldenstrom's disease (WD): A single centre study of 45 cases. Blood. 1998;92(suppl 1):184b; abstr 3776)
  18. Jalal SM, Law ME, Stamberg J, et al.  Detection of diagnostically critical, often hidden, anomalies in complex karyotypes of haematological disorders using multicolour fluorescence in situ hybridization. Br J Haematol. 2001;112:975–980
  19. Schrock E, Veldman T, Padilla-Nash H, et al.  Spectral karyotyping refines cytogenetic diagnostics of constitutional chromosomal abnormalities. Hum Genet. 1997;101:255–262
  20. Sahota SS, Garand R, Bataille R, et al.  VH gene analysis of clonally related IgM and IgG from human lymphoplasmacytoid B-cell tumors with chronic lymphocytic leukemia features and high serum monoclonal IgG. Blood. 1998;91:238–243
  21. Ciric B, VanKeulen V, Rodriguez M, et al.  Clonal evolution in Waldenstrom macroglobulinemia highlights functional role of B-cell receptor. Blood. 2001;97:321–323
  22. Bergsagel PL, Chesi M, Nardini E, et al.  Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. Proc Natl Acad Sci USA. 1996;93:13931–13936
  23. Gabrea A, Bergsagel PL, Chesi M, et al.  Insertion of excised IgH switch sequences causes overexpression of cyclin D1 in a myeloma tumor cell. Mol Cell. 1993;3:119–123
  24. Fonseca R, Oken M, Harrington D, et al.  Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q-arm or monosomy. Leukemia. 2001;15:981–986
  25. Avet-Loiseau H, Daviet A, Saunier S, et al.  Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol. 2001;111:1116–1117
  26. Schop R, Jalal S, Van Wier S, et al.  Deletions of 17p13.1 and 13q14 are uncommon in Waldenstrom macroglobulinemia clonal cells and mostly seen at the time of disease progression. Cancer Genet Cytogenet. 2002;132:55–60
  27. Hirase N, Miyamura T, Ishikura H, et al.  Primary macroglobulinemia with t(11;18) (q21;q21) [Japanese]. Rinsho Ketsueki. 1996;37:340–345
  28. Hirase N, Yufu Y, Abe Y, et al.  Primary macroglobulinemia with t(11;18)(q21;q21). Cancer Genet Cytogenet. 2000;117:113–117
  29. Dierlamm J, Wlodarska I, Michaux L, et al.  Genetic abnormalities in marginal zone B-cell lymphoma. Hematol Oncol. 2000;18:1–13
  30. Remstein ED, James CD, Kurtin PJ. Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol. 2000;156:1183–1188
  31. Bunn PA, Krasnow S, Makuch RW, et al.  Flow cytometric analysis of DNA content of bone marrow cells in patients with plasma cell myeloma: Clinical implications. Blood. 1982;59:528–535
  32. Wong KF, So CC. Waldenstrom macroglobulinemia with karyotypic aberrations involving both homologous 6q. Cancer Genet Cytogenet. 2001;124:137–139
  33. Patau K. Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Lancet. 1961;2:600
  34. Han T, Sadamori N, Takeuchi J, et al.  Clonal chromosome abnormalities in patients with Waldenstrom's and CLL-associated macroglobulinemia: Significance of trisomy 12. Blood. 1983;62:525–531
  35. Broustet A, Veyret V, Moretti G. Chromosomal and cytochemical aspects of Waldenstrom's disease [French]. Ann Biol Clin. 1968;26:17–46
  36. Bottura C, Ferrari I, Veiga A. Chromosomal abnormalities in Waldenstrom's macroglobulinemia. Lancet. 1961;1:1170
  37. Parsa NZ, Gaidano G, Mukherjee AB, et al.  Cytogenetic and molecular analysis of 6q deletions in Burkitt's lymphoma cell lines. Genes Chromosomes Cancer. 1994;9:13–18
  38. Offit K, Parsa NZ, Gaidano G, et al.  6q deletions define distinct clinico-pathologic subsets of non-Hodgkin-'s lymphoma. Blood. 1993;82:2157–2162
  39. Gaidano G, Hauptschein RS, Parsa NZ, et al.  Deletions involving two distinct regions of 6q in B-cell non-Hodgkin lymphoma. Blood. 1992;80:1781–1787
  40. Dohner H, Stilgenbauer S, Benner A, et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916

☆ R.F. is supported by a research grant from the International Waldenstrom Macroglobulinemia Foundation. R.F. is a Clinical Investigator of the Cancer Research Fund of the Damon Runyon Foundation. This work was also supported in part by Public Health Service Grant No. R01 CA83724-01 from the National Cancer Institute (R.F.).

☆☆ Address reprint requests to Rafael Fonseca, MD, Division of Hematology and Internal Medicine, Stabile 628, Rochester, MN 55905.

★ 0093-7754/03/3002-0040$30.00/0

PII: S0093-7754(03)70065-7

doi: 10.1053/sonc.2003.50075

Seminars in Oncology
Volume 30, Issue 2 , Pages 142-145 , April 2003

Article Tools